A Nebraska overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
More than a third of Nebraska adults are living with obesity — 37.6%, per the CDC's 2024 BRFSS survey 3. Factor in the 33.9% the same survey classifies as overweight and 71.5% of the state's adults are above a healthy weight range 3. One likely contributor: 21.6% of Nebraska adults report no leisure-time physical activity at all 3.
Nebraska is home to just over two million people — 2,005,465, per the Census Bureau's Vintage 2024 estimate 5 — spread across long rural distances between Omaha, Lincoln, and everywhere in between.
Nebraska Medicaid's statewide Preferred Drug List (PDL, updated August 3, 2026) lists GLP-1 receptor agonists only under the class "Diabetes Mellitus, Incretin Mimetics/Enhancers." Preferred agents (Ozempic, Trulicity, Victoza) require a Type 2 diabetes diagnosis plus a metformin trial/failure, or an ASCVD diagnosis alongside Type 2 diabetes. Non-preferred agents (Mounjaro, Rybelsus, generic liraglutide) require documented failure of two preferred GLP-1s, a diabetes diagnosis with HbA1c ≥ 7, and a metformin trial or contraindication 12.
Wegovy, Zepbound, and Saxenda — the three brands FDA-labeled specifically for weight management — do not appear anywhere in the 99-page PDL; no "obesity" or "weight loss" drug class exists in the document at all. As of the August 3, 2026 PDL, coverage is gated entirely on a Type 2 diabetes diagnosis, with no documented obesity-indication pathway 1.
Disclosure: this is our own document-analysis reading of the PDL (diagnosis-gated criteria plus total absence of the weight-management brands), not an explicit written "obesity excluded" policy statement from Nebraska DHHS. A secondary corroborating tracker could not be reached in this research pass (KFF brief: blocked; NASHP tracker: 404). Confirm directly with the Nebraska Medicaid Pharmacy Program before treating this as an unqualified claim in any paid or compliance-sensitive context 2.
Because Medicaid coverage is gated on a diabetes diagnosis, most Nebraskans seeking GLP-1 treatment specifically for weight loss are paying out of pocket or through a program like Astra.
Astra's price in Nebraska is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Nebraska-specific price, surcharge, or discount.
We have not yet verified individual clinic cash prices for Nebraska cities — that level of detail is being built city by city, starting with Omaha. Nebraska's median household income is $76,376 (ACS 2024 1-year estimate) 6; a state uninsured rate was not computed for this page and no figure is shown rather than a guessed one.
TODO — Nebraska-specific telehealth prescribing rules for GLP-1 care were not researched for this pass. Board name: TODO — confirm exact board name before publish (likely Nebraska Board of Medicine and Surgery / DHHS Licensure Unit). Board URL: TODO — confirm current, live URL before publish; do not guess. This section is a visible flag for review, not a statement of Nebraska rules.
Astra is licensed to treat patients in Nebraska today, as part of Astra's licensure in all 50 states. Coverage starts with Omaha — see the full Omaha guide for local specialist access and, once researched, local pricing.
Astra treats patients in Nebraska through state-licensed physicians.
Only Omaha has been researched and built as of 2026-08-28. Local Omaha clinic pricing was NOT researched in this state-hub pass and must be sourced separately before the Omaha city page publishes its own local-market table.
Not for weight loss specifically. Nebraska Medicaid's Preferred Drug List (updated August 3, 2026) places GLP-1 drugs only in a diabetes drug class and requires a Type 2 diabetes diagnosis — plus a metformin trial or an ASCVD diagnosis — before any GLP-1 is approved. Wegovy, Zepbound, and Saxenda, the three brands FDA-labeled specifically for weight management, do not appear anywhere in the 99-page document. That's a strong signal there's no obesity-indication coverage pathway today, though it's our own reading of the PDL rather than an explicit DHHS "obesity excluded" statement — confirm directly with the Nebraska Medicaid Pharmacy Program before relying on it for a coverage decision.
We haven't yet verified individual clinic cash prices in Nebraska cities for this page — that level of detail lives on the city pages, starting with Omaha. What we can tell you with certainty is Astra's price: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 total). That price is identical in Nebraska, in every other state, and for every dose — it doesn't change by ZIP code.
37.6% of Nebraska adults have obesity, per the CDC's 2024 BRFSS survey — and another 33.9% are classified overweight, meaning 71.5% of the state's adults are above a healthy weight range. The same survey found 21.6% of Nebraska adults report no leisure-time physical activity at all.
Yes. Astra is licensed to treat patients in all 50 states, including everywhere in Nebraska, not just its two largest cities. Visits happen by video and medication ships directly to you, which matters in a state where a lot of rural residents live a long drive from the nearest endocrinologist or obesity-medicine specialist.
Nebraska Medicaid's preferred GLP-1s — Ozempic, Trulicity, Victoza — are approved because they treat Type 2 diabetes; Mounjaro, Rybelsus, and generic liraglutide sit in a non-preferred tier with tighter prior-authorization rules. None of that PDL touches Wegovy, Zepbound, or Saxenda, the versions of these drugs labeled specifically for weight loss. Astra prescribes semaglutide and tirzepatide specifically for weight management, outside the Medicaid diabetes pathway.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.